Venkata S Avadhanam1, Jim Herold, Simon Thorp, Christopher S C Liu. 1. *Sussex Eye Hospital, Brighton, United Kingdom; †Brighton and Sussex Medical School, Brighton, United Kingdom; ‡Royal Sussex County Hospital, Brighton, United Kingdom; and §Tongdean Eye Clinic, Hove, United Kingdom.
Abstract
PURPOSE: The aim of this study was to report the use of mitomycin-C (MMC) in the treatment of mucous membrane overgrowth in eyes with osteo-odonto-keratoprosthesis (OOKP). METHODS: Records of 4 cases with mucous membrane overgrowth after stage 2 OOKP surgery were reviewed. RESULTS: All the patients had undergone a mucous membrane trimming procedure followed by MMC application. None of the patients had any episode of recurrence of the mucous membrane overgrowth after a single application of MMC in the follow-up period that ranged from 1 to 11 years. CONCLUSIONS: MMC can successfully arrest mucous membrane overgrowth in OOKP-implanted eyes including refractory cases.
PURPOSE: The aim of this study was to report the use of mitomycin-C (MMC) in the treatment of mucous membrane overgrowth in eyes with osteo-odonto-keratoprosthesis (OOKP). METHODS: Records of 4 cases with mucous membrane overgrowth after stage 2 OOKP surgery were reviewed. RESULTS: All the patients had undergone a mucous membrane trimming procedure followed by MMC application. None of the patients had any episode of recurrence of the mucous membrane overgrowth after a single application of MMC in the follow-up period that ranged from 1 to 11 years. CONCLUSIONS:MMC can successfully arrest mucous membrane overgrowth in OOKP-implanted eyes including refractory cases.